Venetoclax grabs third FDA ‘breakthrough’ for blood cancer

Alok Saboo

AbbVie and Roche's has received yet another accelerated review from the FDA–this time in patients with the most common type of acute leukemia.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS